METex14sk testing to access tepotinib on the PBS - new item 73436

This page provides information about the listing of new pathology MBS item 73436

Page last updated: 28 October 2022

From 1 November 2022, new pathology MBS item 73436 will be introduced for MET proto-oncogene, receptor tyrosine kinase (MET) exon 14 skipping alterations (METex14sk) testing in patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) to determine eligibility for treatment with tepotinib under the Pharmaceutical Benefits Scheme.

The Pharmaceutical Benefits Advisory Committee (PBAC) recommended the listing of tepotinib for the treatment of patients with locally advanced or metastatic METex14sk-positive NSCLC. The Medical Services Advisory Committee (MSAC) supported the creation of a new MBS item to support patients undergoing METex14sk testing.

Further information is available in the following factsheets:

PDF Version Factsheet for Pathology MBS item for METex14sk testing (PDF 148 KB)
Word Version Factsheet for Pathology MBS item for METex14sk testing (Word 128 KB)

In this section